ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2,1,Muscle twitching,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3,1,Application site dermatitis,Application site reactions,Administration site reactions,Genrl,N
4,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,2,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
5,1,Application site discomfort,Application site reactions,Administration site reactions,Genrl,N
5,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
5,3,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
6,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
7,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
9,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
9,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
9,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
9,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
10,1,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
11,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
12,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
12,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
13,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
13,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
13,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
13,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
14,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
14,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
15,1,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
16,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
16,2,Physical assault,Criminal activity,Legal issues,SocCi,N
17,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
17,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
18,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
18,2,Muscle rigidity,Muscle tone abnormalities,Muscle disorders,Musc,N
18,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
18,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
18,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
19,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
20,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
20,2,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
20,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
20,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
20,5,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
21,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
21,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
21,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
22,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
22,2,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
22,3,Immobile,Disability issues,Lifestyle issues,SocCi,N
22,4,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
22,5,Pelvic discomfort,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
23,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
23,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
23,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
24,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
25,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
26,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
28,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
29,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
29,2,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
29,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
30,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
30,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
30,3,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
31,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
32,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
32,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
33,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
33,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
33,4,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
33,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
34,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
35,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
36,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
36,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
36,3,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
37,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
37,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
37,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
37,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
37,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
37,6,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
38,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
38,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,1,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
40,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
40,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
41,2,Obsessive-compulsive disorder,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
42,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,1,"Hallucination, auditory",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
44,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
44,2,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
45,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
46,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
47,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
48,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
49,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
50,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
51,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
52,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
52,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
53,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
53,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
54,1,Application site hypersensitivity,Application site reactions,Administration site reactions,Genrl,N
54,2,Application site rash,Application site reactions,Administration site reactions,Genrl,N
54,3,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
55,1,Giant cell arteritis,Arterial infections and inflammations,Vascular infections and inflammations,Vasc,N
55,2,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
55,3,Meningioma,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
55,4,Visual field defect,Visual field disorders,Vision disorders,Eye,N
56,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
56,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
56,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
56,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
57,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
58,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
59,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
60,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
61,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
61,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
62,1,Compulsive shopping,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
63,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
64,1,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
64,2,Sudden onset of sleep,Sleep disturbances NEC,Sleep disturbances (incl subtypes),Nerv,N
65,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
66,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
66,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
67,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
68,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
68,2,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
68,3,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
68,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
68,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
68,6,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
69,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
69,2,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
70,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
70,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
71,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
72,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
72,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
73,1,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
73,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
74,1,Application site discomfort,Application site reactions,Administration site reactions,Genrl,N
74,2,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
75,1,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
75,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
76,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
76,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
76,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
76,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
77,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
77,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
77,3,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
77,4,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
77,5,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
77,6,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
77,7,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
77,8,Dysphemia,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
77,9,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
77,10,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
77,11,Feeling drunk,Feelings and sensations NEC,General system disorders NEC,Genrl,N
77,12,Headache,Headaches NEC,Headaches,Nerv,N
77,13,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
77,14,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
77,15,Miosis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
77,16,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
77,17,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
77,18,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
77,19,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
77,20,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
77,21,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
77,22,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
77,23,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
77,24,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
78,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
79,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
80,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
80,2,Device connection issue,Device issues NEC,Device issues,Prod,N
80,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
81,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
81,2,Post inflammatory pigmentation change,Pigmentation changes NEC,Pigmentation disorders,Skin,N
82,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
82,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
82,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
82,4,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
83,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
84,1,Femoral neck fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
85,1,Knee arthroplasty,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
86,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
86,2,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
86,3,Sunburn,Radiation injuries,Injuries by physical agents,Inj&P,N
87,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
88,1,Gambling,Social issues NEC,Lifestyle issues,SocCi,N
88,2,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
88,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
89,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
89,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
89,3,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
89,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
89,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
89,6,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
89,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
89,8,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
89,9,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
89,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
89,11,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
89,12,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
89,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
90,1,"Hallucinations, mixed",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
91,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
91,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
92,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
92,2,Aortic aneurysm rupture,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,Y
92,3,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
92,4,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
93,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
93,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
93,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
93,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
94,1,Acute respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
95,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
95,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
96,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
97,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
97,2,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
98,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
98,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
99,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
100,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
101,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
101,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
101,3,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
101,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
102,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
102,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
102,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
103,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
103,2,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
103,3,Dopamine dysregulation syndrome,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
103,4,Drug abuse,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
103,5,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
103,6,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
103,7,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
103,8,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
103,9,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
103,10,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
103,11,Obsessive-compulsive disorder,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
104,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
104,2,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
104,3,Foaming at mouth,General signs and symptoms NEC,General system disorders NEC,Genrl,N
104,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
104,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
104,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
104,7,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
104,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
105,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
105,2,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
105,3,Obsessive-compulsive disorder,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
106,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
106,2,Metastatic squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
107,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
107,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
107,3,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
108,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
108,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
109,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
109,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
109,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
109,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
109,5,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
109,6,Wheelchair user,Disability issues,Lifestyle issues,SocCi,N
110,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
110,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
111,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
111,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
111,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
111,4,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
111,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
112,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
112,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
112,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
112,4,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
112,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
112,6,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
112,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
112,8,Pneumonia aspiration,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
112,9,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
112,10,Seborrhoea,Sebaceous gland disorders,Skin appendage conditions,Skin,N
113,1,Dopamine dysregulation syndrome,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
113,2,Drug abuse,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
114,1,Delusion,Delusional symptoms,Disturbances in thinking and perception,Psych,N
114,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
114,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
115,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
115,2,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
115,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
116,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
117,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
117,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
117,3,Application site rash,Application site reactions,Administration site reactions,Genrl,N
118,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
119,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
119,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
119,3,Bradyphrenia,Thinking disturbances,Disturbances in thinking and perception,Psych,N
119,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
119,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
119,6,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
119,7,Muscle rigidity,Muscle tone abnormalities,Muscle disorders,Musc,N
119,8,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
119,9,Parkinsonism,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
119,10,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
120,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
120,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
120,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
121,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
121,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
121,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
121,4,Obsessive thoughts,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
121,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
121,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
122,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
122,2,Obsessive-compulsive disorder,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
122,3,Stereotypy,Stereotypies and automatisms,Changes in physical activity,Psych,N
123,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
123,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
124,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
124,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
124,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
125,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
125,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
125,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
126,1,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
126,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
127,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
128,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
129,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
130,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
131,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
132,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
132,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
132,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
132,4,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
132,5,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
133,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
133,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
134,1,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
134,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
134,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
134,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
135,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
135,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
136,1,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
136,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
137,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
137,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
137,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
138,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
138,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
138,3,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
139,1,Brain tumour operation,Skull and brain therapeutic procedures,"Nervous system, skull and spine therapeutic procedures",Surg,N
140,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
140,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
141,1,Acute psychosis,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
142,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
143,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
144,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
144,2,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
145,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
145,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
146,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
147,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
147,2,Periodic limb movement disorder,Sleep disturbances NEC,Sleep disturbances (incl subtypes),Nerv,N
148,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
148,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
148,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
148,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
149,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
150,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
150,2,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
150,3,Impulsive behaviour,Impulse control disorders,Impulse control disorders NEC,Psych,N
150,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
150,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
150,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
151,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
151,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
152,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
152,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
153,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
154,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
155,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
155,2,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
155,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
155,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
156,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
156,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
157,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
158,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
158,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
159,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
159,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
159,3,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
160,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
160,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
161,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
162,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
162,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
162,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,4,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
162,5,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
162,6,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
162,7,Terminal state,General signs and symptoms NEC,General system disorders NEC,Genrl,N
163,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
163,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
163,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
163,4,Type 1 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
164,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
165,1,Hyperthermia,Body temperature altered,Body temperature conditions,Genrl,N
165,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
165,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
166,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
166,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
166,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
166,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
167,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
167,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
168,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
169,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
169,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
170,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
170,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
170,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
171,1,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
172,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
173,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
173,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
173,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
173,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
174,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
174,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
174,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
174,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
174,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
175,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
175,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
176,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
176,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
177,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
178,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
178,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
179,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
179,2,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
179,3,Motor dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
180,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
180,2,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
180,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
180,4,Wound secretion,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
181,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
181,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
181,3,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
182,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
183,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
183,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
183,3,Femoral neck fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
184,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
185,1,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
185,2,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
185,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
185,4,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
185,5,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
185,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
185,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
186,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
186,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
186,3,Intestinal pseudo-obstruction,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
187,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
188,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
189,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
189,2,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
190,1,Emergency care,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
191,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
191,2,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
192,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
192,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
192,3,Microangiopathy,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
193,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
194,1,Product formulation issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
194,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
195,1,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
196,1,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
196,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
196,3,Sexual abuse,Criminal activity,Legal issues,SocCi,N
196,4,Wheelchair user,Disability issues,Lifestyle issues,SocCi,N
197,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
197,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
197,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
197,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
197,5,Radius fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
198,1,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
198,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
198,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
199,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
199,2,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
199,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
199,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
199,5,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
200,1,Application site dermatitis,Application site reactions,Administration site reactions,Genrl,N
200,2,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
200,3,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
201,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
201,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
202,1,Cardiac pacemaker insertion,Cardiac device therapeutic procedures,Cardiac therapeutic procedures,Surg,N
202,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
202,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
203,1,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
204,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
205,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
206,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
206,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
207,1,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
208,1,Compulsive sexual behaviour,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
208,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
209,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
209,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
209,3,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
210,1,Excessive masturbation,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
210,2,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
210,3,Libido increased,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
211,1,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
212,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
213,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
214,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
214,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
215,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
215,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
216,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
217,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
218,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
219,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
220,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
220,2,Application site urticaria,Application site reactions,Administration site reactions,Genrl,N
220,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
221,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
221,2,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
222,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
222,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
222,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
223,1,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
224,1,Rehabilitation therapy,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
225,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
226,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
226,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
226,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
226,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
227,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
228,1,Sleep attacks,Narcolepsy and associated conditions,Sleep disorders and disturbances,Psych,N
228,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
229,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
230,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
230,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
231,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
231,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
231,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
231,4,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
232,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
232,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
232,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
233,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
233,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
234,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
234,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
234,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
235,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
235,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
236,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
236,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
236,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
236,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
237,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
238,1,Apraxia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
238,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
238,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
238,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
238,5,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
238,6,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
238,7,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
238,8,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
238,9,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
238,10,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
238,11,Mutism,Communications disorders,Communication disorders and disturbances,Psych,N
238,12,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
238,13,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
238,14,Nuchal rigidity,Muscle tone abnormalities,Muscle disorders,Musc,N
238,15,Parkinsonism,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
238,16,Quadriparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
238,17,Resting tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
238,18,Tardive dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
238,19,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
238,20,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
238,21,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
239,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
239,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
240,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
240,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
241,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
241,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
242,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
242,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
242,3,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
243,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
243,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
243,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
243,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
244,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
244,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
244,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
245,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
246,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
246,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
246,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
247,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
247,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
247,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
248,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
249,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
249,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
250,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
250,2,Coordination abnormal,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
250,3,Freezing phenomenon,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
250,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
250,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
251,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
251,2,Diabetic foot,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
251,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
252,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
252,2,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
252,3,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
252,4,Confusion postoperative,Neurological and psychiatric procedural complications,Procedural related injuries and complications NEC,Inj&P,N
252,5,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
252,6,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
252,7,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
252,8,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
253,1,Application site hypersensitivity,Application site reactions,Administration site reactions,Genrl,N
254,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
254,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
255,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
255,2,Application site ulcer,Application site reactions,Administration site reactions,Genrl,N
255,3,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
255,4,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
256,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
256,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
257,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
257,2,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
258,1,Alcohol use,Alcohol product use,Lifestyle issues,SocCi,N
258,2,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
258,3,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
258,4,Hostility,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
258,5,Parkinsonism,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
258,6,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
259,1,Blood pressure diastolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
259,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
260,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
260,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
261,1,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
262,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
262,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
263,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
263,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
264,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
265,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
265,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
266,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
267,1,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
267,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
267,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
268,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
268,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
268,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
268,4,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
268,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
269,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
270,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
271,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
271,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
271,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
271,4,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
271,5,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
271,6,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
271,7,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
271,8,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
271,9,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,10,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,11,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
271,12,Headache,Headaches NEC,Headaches,Nerv,N
271,13,Hyperkinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
271,14,Hypertensive heart disease,Cardiac hypertensive complications,"Cardiac disorders, signs and symptoms NEC",Card,N
271,15,Immobile,Disability issues,Lifestyle issues,SocCi,N
271,16,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
271,17,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
271,18,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
271,19,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
271,20,Morose,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
271,21,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
271,22,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
271,23,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
271,24,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
271,25,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
271,26,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
271,27,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
271,28,Suspected counterfeit product,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
271,29,Therapeutic response changed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,30,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,31,Visual field defect,Visual field disorders,Vision disorders,Eye,N
272,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
272,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
272,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
272,4,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
272,5,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
272,6,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
272,7,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
272,8,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
272,9,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,10,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,11,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
272,12,Headache,Headaches NEC,Headaches,Nerv,N
272,13,Hyperkinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
272,14,Hypertensive heart disease,Cardiac hypertensive complications,"Cardiac disorders, signs and symptoms NEC",Card,N
272,15,Immobile,Disability issues,Lifestyle issues,SocCi,N
272,16,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
272,17,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
272,18,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
272,19,Morose,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
272,20,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
272,21,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,22,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,23,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
272,24,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,25,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
272,26,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
272,27,Suspected counterfeit product,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,28,Therapeutic response changed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,29,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,30,Visual field defect,Visual field disorders,Vision disorders,Eye,N
273,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
274,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
274,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
274,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
274,4,Prostatic operation,Prostatic therapeutic procedures,Male genital tract therapeutic procedures,Surg,N
275,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
276,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
276,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
276,3,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
276,4,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
276,5,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
276,6,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
276,7,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
276,8,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
277,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
277,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
277,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
278,1,Compulsive shopping,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
279,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
280,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
280,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
280,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
280,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
281,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
281,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
281,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
281,4,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
282,1,Intestinal pseudo-obstruction,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
283,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
284,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
284,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
285,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
285,2,Stoma obstruction,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
286,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
286,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
286,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
286,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
287,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
287,2,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
287,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
288,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
288,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
288,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
288,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
289,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
290,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
291,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
291,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
291,3,Application site pain,Application site reactions,Administration site reactions,Genrl,N
291,4,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
292,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
293,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
293,2,Obsessive-compulsive personality disorder,Personality disorders with anxious behaviour (Cluster C),Personality disorders and disturbances in behaviour,Psych,N
294,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
295,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
295,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
295,3,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
295,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
295,5,Tongue movement disturbance,Tongue signs and symptoms,Tongue conditions,Gastr,N
296,1,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
296,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
296,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
296,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
297,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
297,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
297,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
297,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
298,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
298,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
298,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
300,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
300,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
300,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
300,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
300,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
300,6,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
300,7,Suicidal behaviour,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
300,8,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
301,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
301,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
302,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
302,2,Excessive eye blinking,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
302,3,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
302,4,Food craving,Appetite disorders,Appetite and general nutritional disorders,Metab,N
302,5,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
302,6,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
302,7,Lack of spontaneous speech,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
302,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
302,9,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
302,10,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
302,11,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
302,12,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
302,13,Slow speech,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
302,14,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
302,15,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
302,16,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
302,17,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
302,18,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
303,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
303,2,Application site warmth,Application site reactions,Administration site reactions,Genrl,N
303,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
303,4,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
304,1,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
305,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
306,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
307,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
307,2,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
307,3,Gastrointestinal inflammation,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
308,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
308,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
308,3,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
308,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
308,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
309,1,Acute psychosis,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
310,1,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
311,1,Gambling,Social issues NEC,Lifestyle issues,SocCi,N
312,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
312,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
313,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
314,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
314,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
315,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
315,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
315,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
315,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
316,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
316,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
316,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
317,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
317,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
317,3,Sudden onset of sleep,Sleep disturbances NEC,Sleep disturbances (incl subtypes),Nerv,N
318,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
318,2,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
318,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
319,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
320,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
320,2,Application site rash,Application site reactions,Administration site reactions,Genrl,N
320,3,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
321,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
321,2,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
322,1,Kidney infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
322,2,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
323,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
324,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
324,2,Stupor,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
325,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
325,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
325,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
325,4,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
325,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
326,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
326,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
326,3,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
326,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
327,1,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
328,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
329,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
329,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
330,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
330,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
331,1,Communication disorder,Communications disorders,Communication disorders and disturbances,Psych,N
331,2,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
331,3,Fluid intake reduced,Fluid intake decreased,Electrolyte and fluid balance conditions,Metab,N
331,4,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
331,5,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
332,1,Application site erosion,Application site reactions,Administration site reactions,Genrl,N
332,2,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
333,1,Disinhibition,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
333,2,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
333,3,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
333,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
333,5,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
334,1,Parosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
334,2,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
335,1,Blood pressure abnormal,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
335,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
335,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
336,1,Drug dose titration not performed,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
336,2,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
337,1,Lip oedema,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
337,2,Tongue oedema,Tongue signs and symptoms,Tongue conditions,Gastr,N
338,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
338,2,Extrapyramidal disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
338,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
338,4,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
339,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
339,3,Parkinsonian crisis,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
339,4,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
339,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
340,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
340,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
341,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
342,1,Electric shock sensation,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
342,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
342,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
343,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
343,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
343,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
344,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
344,2,Application site rash,Application site reactions,Administration site reactions,Genrl,N
344,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
344,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
344,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
344,6,Muscle twitching,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
344,7,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
344,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
344,9,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
344,10,Product shape issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
344,11,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
345,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
346,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
346,2,Impulsive behaviour,Impulse control disorders,Impulse control disorders NEC,Psych,N
347,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
347,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
347,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
347,4,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
348,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
348,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
349,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
350,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
351,1,Application site dermatitis,Application site reactions,Administration site reactions,Genrl,N
352,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
352,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
353,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
353,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
353,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
354,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
354,2,Impulsive behaviour,Impulse control disorders,Impulse control disorders NEC,Psych,N
354,3,Psychiatric symptom,Psychiatric symptoms NEC,Psychiatric and behavioural symptoms NEC,Psych,N
354,4,Sexual abuse,Criminal activity,Legal issues,SocCi,N
355,1,Dropped head syndrome,Neuromuscular disorders NEC,Neuromuscular disorders,Nerv,N
356,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
357,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
357,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
357,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
357,4,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
358,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
358,2,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
358,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
358,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
359,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
359,2,Counterfeit product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
359,3,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
359,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,5,Hyperkinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
359,6,Hypertensive heart disease,Cardiac hypertensive complications,"Cardiac disorders, signs and symptoms NEC",Card,N
359,7,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
359,8,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
359,9,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
359,10,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
359,11,Visual field defect,Visual field disorders,Vision disorders,Eye,N
360,1,Euphoric mood,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
360,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
360,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
360,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
361,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
361,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
361,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
361,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
362,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
362,2,Eyelid disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
362,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
362,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
363,1,Menstrual disorder,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
363,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
363,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
364,1,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
365,1,Application site dryness,Application site reactions,Administration site reactions,Genrl,N
365,2,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
365,3,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
366,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
366,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
366,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
366,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
367,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
367,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
367,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
367,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
367,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
368,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
368,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
369,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
369,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
370,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
370,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
371,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
371,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
372,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
372,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
372,3,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
373,1,Aphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
373,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
373,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
373,4,Communication disorder,Communications disorders,Communication disorders and disturbances,Psych,N
373,5,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
373,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
373,7,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
373,8,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
374,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
374,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
374,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
374,4,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
374,5,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
374,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
374,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
374,8,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
375,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
376,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
376,2,Application site exfoliation,Application site reactions,Administration site reactions,Genrl,N
376,3,Application site haemorrhage,Application site reactions,Administration site reactions,Genrl,N
376,4,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
376,5,Application site pain,Application site reactions,Administration site reactions,Genrl,N
376,6,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
377,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
378,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
379,1,Burning feet syndrome,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
379,2,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
380,1,Device adhesion issue,Device issues NEC,Device issues,Prod,N
381,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
381,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
381,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
381,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
382,1,Device adhesion issue,Device issues NEC,Device issues,Prod,N
383,1,Application site bruise,Application site reactions,Administration site reactions,Genrl,N
383,2,Application site discharge,Application site reactions,Administration site reactions,Genrl,N
383,3,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
383,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
384,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
385,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
386,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
386,2,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
386,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
387,1,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
387,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
387,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
388,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
388,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
389,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
389,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
390,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
391,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
392,1,Impulse-control disorder,Impulse control disorders,Impulse control disorders NEC,Psych,N
393,1,Device adhesion issue,Device issues NEC,Device issues,Prod,N
393,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
394,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
394,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
395,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
395,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
395,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
396,1,Dystonia,Dystonias,Movement disorders (incl parkinsonism),Nerv,N
396,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
396,3,Neuroleptic malignant syndrome,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
396,4,Parkinsonian crisis,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
397,1,Device adhesion issue,Device issues NEC,Device issues,Prod,N
397,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
398,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
398,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
399,1,Device adhesion issue,Device issues NEC,Device issues,Prod,N
399,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
400,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
400,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
400,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
401,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
402,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
402,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
403,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
403,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
403,3,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
404,1,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
405,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
406,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
406,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
407,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
407,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
407,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
408,1,Neglect of personal appearance,Psychiatric symptoms NEC,Psychiatric and behavioural symptoms NEC,Psych,N
408,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
409,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
409,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
409,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
410,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
410,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
411,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
412,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
412,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
412,3,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
412,4,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
413,1,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
413,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
413,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
414,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
415,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
415,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
416,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
416,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
416,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
416,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
417,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
417,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
417,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
417,4,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
417,5,Salivary hypersecretion,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
417,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
418,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
419,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
420,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
421,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
421,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
422,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
422,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
423,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
423,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
424,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
424,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
425,1,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
425,2,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
425,3,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
425,4,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
425,5,Tearfulness,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
426,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
426,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
427,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
428,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
428,2,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
428,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
429,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
430,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
431,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
431,2,Ocular hyperaemia,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
431,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
432,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
433,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
433,2,Bedridden,Disability issues,Lifestyle issues,SocCi,N
433,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
433,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
433,5,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
433,6,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
433,7,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
433,8,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
433,9,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
433,10,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
434,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
435,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
435,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
436,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
436,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
436,3,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
437,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
438,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
438,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
439,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
439,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
440,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
441,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
442,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
442,2,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
442,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
442,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
443,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
444,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
444,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
445,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
445,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
446,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
446,2,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
447,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
448,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
449,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
449,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
449,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
450,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
450,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
451,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
451,2,Choking sensation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
451,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
452,1,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
452,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
453,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
453,2,Miosis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
453,3,Muscle twitching,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
454,1,Gambling disorder,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
455,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
455,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
455,3,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
455,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
455,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
455,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
455,7,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
456,1,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
457,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
458,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
459,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
459,2,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
460,1,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
460,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
461,1,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
461,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
462,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
462,2,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
463,1,Migraine,Migraine headaches,Headaches,Nerv,N
464,1,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
465,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
466,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
466,2,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
467,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
467,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
467,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
468,1,Hypersexuality,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
468,2,Marital problem,Family and partner issues,Family issues,SocCi,N
469,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
469,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
470,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
470,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
471,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
472,1,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
473,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
474,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
474,2,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
475,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
475,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
475,3,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
476,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
476,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
